Table 2 Immunological profile and histopathological characteristics of the studied RPGN patients

Low C3 (%)

2 (10%)

42 (87.5%)

0 (0%)

Low C4 (%)

0 (0%)

34 (70.8%)

0 (0%)

+ve ANA (%)

0 (0%)

34 (70.8%)

0 (0%)

+ve AntidsDNA (%)

0 (0%)

34 (70.8%)

0 (0%)

+ve AntiGBM Ab (%)

16 (80%)

0 (0%)

0 (0%)

+ve P-ANCA (%)

0 (0%)

0 (0%)

13 (39.4%)

+ve C-ANCA (%)

0 (0%)

0 (0%)

8 (24.2%)

Total number of glomeruli

20 (4)

15–26

20 (6.75)

12–30

17 (8)

12–24

Number of normal glomeruli

3.0 (1)

1–6

4 (3)

1–14

4 (2)

0–10

Number of sclerotic glomeruli

7 (6)

0–9

4 (4)

0–8

3 (6)

0–7

Number of crescentic glomeruli

11.5 (4)

9–15

11 (3)

7–19

12 (5.5)

5–15

Number of fibrous crescents

3 (2)

1–7

2.5 (1.75)

0–5

2 (3)

0–6

Number of cellular crescents

8.5 (3)

5–12

9 (4.75)

5–16

8 (6)

4–14

Glomerular lesions (%)

 • Endocapillary proliferation (%)

 • Mesangial proliferation (%)

 • Neutrophilic infiltration (%)

 • Glomerular thrombosis (%)

0 (0%)

10 (50%)

12 (60%)

2 (10%)

48 (100%)

26 (54.2%)

32 (66.7%)

0 (0%)

2 (6.1%)

15 (45.5%)

23 (69.7%)

7 (21.2%)

Moderate to severe IFTA (%)

14 (70%)

24 (50%)

16 (48.5%)

TLO formation (%)

10 (50%)

22 (45.8%)

16 (48.5%)

Vascular lesions

 • Fibrinoid necrosis (%)

 • Degree of severe arteriosclerosis (%)

3 (15%)

8 (40%)

15 (31.3%)

26 (54.2%)

13 (39.4%)

14 (42.4%)

Treatment

Steroid, CYC as induction then steroid, AZA as maintenance

0 (0%)

30 (62.5%)

29 (87.9%)

Steroid, rituximab

0 (0%)

6 (12.5%)

4 (12.1%)

Steroid, CYC, plasmapheresis as induction then steroid, AZA as maintenance

20 (100%)

12 (25%)

0 (0%)